X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs GLENMARK PHARMA - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES GLENMARK PHARMA DIVIS LABORATORIES/
GLENMARK PHARMA
 
P/E (TTM) x 30.0 12.2 246.1% View Chart
P/BV x 5.2 3.2 161.3% View Chart
Dividend Yield % 1.0 0.4 254.3%  

Financials

 DIVIS LABORATORIES   GLENMARK PHARMA
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-17
GLENMARK PHARMA
Mar-17
DIVIS LABORATORIES/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,222993 123.1%   
Low Rs784729 107.5%   
Sales per share (Unadj.) Rs153.1325.5 47.0%  
Earnings per share (Unadj.) Rs39.939.3 101.7%  
Cash flow per share (Unadj.) Rs44.648.7 91.6%  
Dividends per share (Unadj.) Rs10.002.00 500.0%  
Dividend yield (eoy) %1.00.2 429.3%  
Book value per share (Unadj.) Rs201.8159.2 126.8%  
Shares outstanding (eoy) m265.47282.17 94.1%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x6.62.6 247.7%   
Avg P/E ratio x25.121.9 114.6%  
P/CF ratio (eoy) x22.517.7 127.1%  
Price / Book Value ratio x5.05.4 91.9%  
Dividend payout %25.05.1 491.8%   
Avg Mkt Cap Rs m266,266242,991 109.6%   
No. of employees `0009.713.0 75.1%   
Total wages/salary Rs m4,68716,408 28.6%   
Avg. sales/employee Rs Th4,175.07,083.9 58.9%   
Avg. wages/employee Rs Th481.51,265.4 38.1%   
Avg. net profit/employee Rs Th1,089.3855.1 127.4%   
INCOME DATA
Net Sales Rs m40,64391,857 44.2%  
Other income Rs m749374 200.4%   
Total revenues Rs m41,39292,230 44.9%   
Gross profit Rs m14,46020,367 71.0%  
Depreciation Rs m1,2332,644 46.7%   
Interest Rs m232,373 1.0%   
Profit before tax Rs m13,95315,724 88.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-810 0.0%   
Tax Rs m3,3493,827 87.5%   
Profit after tax Rs m10,60411,088 95.6%  
Gross profit margin %35.622.2 160.5%  
Effective tax rate %24.024.3 98.6%   
Net profit margin %26.112.1 216.2%  
BALANCE SHEET DATA
Current assets Rs m40,10568,746 58.3%   
Current liabilities Rs m6,59527,027 24.4%   
Net working cap to sales %82.545.4 181.5%  
Current ratio x6.12.5 239.1%  
Inventory Days Days11985 139.5%  
Debtors Days Days8196 84.5%  
Net fixed assets Rs m19,99524,132 82.9%   
Share capital Rs m531282 188.1%   
"Free" reserves Rs m53,04344,643 118.8%   
Net worth Rs m53,57444,925 119.3%   
Long term debt Rs m045,363 0.0%   
Total assets Rs m61,585117,639 52.4%  
Interest coverage x618.47.6 8,109.7%   
Debt to equity ratio x01.0 0.0%  
Sales to assets ratio x0.70.8 84.5%   
Return on assets %17.311.4 150.8%  
Return on equity %19.824.7 80.2%  
Return on capital %26.119.1 136.2%  
Exports to sales %00-   
Imports to sales %25.20-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m10,259NA-   
Fx inflow Rs m35,38456,152 63.0%   
Fx outflow Rs m10,3998,084 128.6%   
Net fx Rs m24,98548,068 52.0%   
CASH FLOW
From Operations Rs m11,4936,574 174.8%  
From Investments Rs m-11,372-7,124 159.6%  
From Financial Activity Rs m-935,432 -1.7%  
Net Cashflow Rs m281,992 1.4%  

Share Holding

Indian Promoters % 52.0 48.3 107.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 6.9 171.0%  
FIIs % 19.0 34.4 55.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 10.5 163.8%  
Shareholders   31,796 56,727 56.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   J.B.CHEMICALS  SUVEN LIFE  CIPLA  CADILA HEALTHCARE  VENUS REMEDIES  

Compare DIVIS LABORATORIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Firm US Markets; Sun Pharma, Software Stocks & Other Top Cues to Sway the Markets Today(Pre-Open)

Indian share markets finished the previous trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views on News

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

A New Quest for the Stock Market's MOST Profitable Ideas...(Smart Contrarian)

Feb 23, 2018

If you want to receive the best ideas in the Indian stick markets...you need to heed this important announcement.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Feb 23, 2018 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 5-YR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS